Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Longeveron Inc.LGVN · healthcare | |
|---|---|
| Grade |  Eweakest fifth of 371 graded peers; percentile 96.8, sampling error 2.5 points; lower is stronger |
| Rank | 359 of 371 |
| Profitability | Dpercentile 63.3 |
| Solvency | Epercentile 86.6 |
| Growth and financing | D/Epercentile 81.8 |
| Reliability | 0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| Peer failure rate | 0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | under $12.5M assetstotal assets $10.3M[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | short runwaynot computable: dilution, distress, fortress balance sheet |
| Inputs computable | 7 of 14 |
| Graded from | filings received through Mar 17, 2026206 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $2.382026-10-08; market equity $0; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 17, 2026; the document on sec.gov.
We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. Laromestrocel possesses broad potential applications across a spectrum of disease areas.
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 63.3 | |||||||
| Gross profitability | 7.8% | [1,4] | 32.2% | 78.7 | 372 | 2025-12-31 | |
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (22.7%) | [1,5-7] | (6.6%) | 19.1 | 811 | 2025-12-31 | |
| Gross margin stability, five years | 17.6 pts | [2,4,8-15] | 2.8 pts | 92.1 | 243 | 2025-12-31 | |
| Solvency, sleeve percentile 86.6 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| liabilities and a nearby cover-page share count are required at 2026-06-30 | |||||||
| Altman Z double-prime | (55.12) | [1,16-21] | (0.31) | 89.7 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31 | |||||||
| Current ratio | 1.33x | [16-17] | 2.96x | 83.5 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 81.8 | |||||||
| Revenue growth, three-year compound | (0.6%) | [2,9,11,13] | 10.0% | 72.2 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| one or more required annual facts are missing | |||||||
| Asset growth, three years | (27.9%) | [1,7,22-23] | 2.1% | 91.3 | 704 | 2025-12-31 | |
| Net share issuance, one year | not computable | 2.5% | |||||
| two annual share counts are required; found 0 | |||||||
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.565; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 354 | ALX Oncology Holdings Inc. (ALXO) ALX Oncology Holdings Inc. (ALXO) Eweakest fifth; percentile 95.4 Nasdaq · Pharmaceutical Preparations market equity $163.2M; last close $1.18 Warnings: dilution, short runway, degenerate inputs, fortress balance sheet; 8 of 14 inputs | 95.4 | E | dilution, short runway, degenerate inputs, fortress balance sheet |
| 355 | Biomerica Inc. (BMRA) Biomerica Inc. (BMRA) Eweakest fifth; percentile 95.7 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $8.7M; last close $1.87 Warnings: short runway; 7 of 14 inputs | 95.7 | E | short runway |
| 356 | Bolt Biotherapeutics, Inc. (BOLT) Bolt Biotherapeutics, Inc. (BOLT) Eweakest fifth; percentile 95.9 Nasdaq · Pharmaceutical Preparations market equity $7.0M; last close $3.61 Warnings: short runway, distress; 7 of 14 inputs | 95.9 | E | short runway, distress |
| 357 | Pfizer Inc. (PFE) Pfizer Inc. (PFE) Eweakest fifth; percentile 96.2 NYSE · Pharmaceutical Preparations market equity $158.6B; last close $27.83 No active warnings; 8 of 14 inputs | 96.2 | E | |
| 358 | Dare Bioscience, Inc. (DARE) Dare Bioscience, Inc. (DARE) Eweakest fifth; percentile 96.5 Nasdaq · Pharmaceutical Preparations market equity $11.8M; last close $0.76 Warnings: dilution; 7 of 14 inputs | 96.5 | E | dilution |
| 359 | Longeveron Inc. (LGVN) Longeveron Inc. (LGVN) Eweakest fifth; percentile 96.8 Nasdaq · Pharmaceutical Preparations last close $2.38 Warnings: short runway; 7 of 14 inputs | 96.8 | E | short runway |
| 360 | Clene Inc. (CLNN) Clene Inc. (CLNN) Eweakest fifth; percentile 97.0 Nasdaq · Pharmaceutical Preparations market equity $49.9M; last close $3.88 Warnings: dilution, distress; 8 of 14 inputs | 97.0 | E | dilution, distress |
| 361 | Agenus Inc. (AGEN) Agenus Inc. (AGEN) Eweakest fifth; percentile 97.3 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $339.5M; last close $7.53 Warnings: dilution, short runway; 7 of 14 inputs | 97.3 | E | dilution, short runway |
| 362 | Nektar Therapeutics (NKTR) Nektar Therapeutics (NKTR) Eweakest fifth; percentile 97.6 Nasdaq · Pharmaceutical Preparations market equity $1.4B; last close $40.77 Warnings: dilution, short runway; 8 of 14 inputs | 97.6 | E | dilution, short runway |
| 363 | Vyome Holdings, Inc. (HIND) Vyome Holdings, Inc. (HIND) Eweakest fifth; percentile 97.8 Nasdaq · Pharmaceutical Preparations market equity $14.2M; last close $2.03 Warnings: dilution, late filer, fortress balance sheet; 8 of 14 inputs | 97.8 | E | dilution, late filer, fortress balance sheet |
| 364 | Sintx Technologies, Inc. (SINT) Sintx Technologies, Inc. (SINT) Eweakest fifth; percentile 98.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $14.1M; last close $2.11 Warnings: dilution, short runway; 8 of 14 inputs | 98.1 | E | dilution, short runway |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | E | 96.5 | 2204 |
| sector peers, equal sleeves (the grade) | E | 96.8 | 371 |
| same exchange, equal sleeves | E | 96.2 | 1219 |
| sector peers, equal inputs | E | 95.9 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 819.9% | 8.0% | 100 | hotter than 100 of 100 peers |
| Distance from 52-week high | (71.9%) | (31.4%) | 11 | closer to its high than 11 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | not computable | (1.0%) | required accounting or market input is missing | |
| Book value to price | not computable | 0.28 | required accounting or market input is missing | |
| Sales to price | not computable | 0.31 | required accounting or market input is missing | |
| Composite equity issuance, five years | not computable | 20.3% | required accounting or market input is missing | |
| Relative strength against the sector, log excess return | 2.01 | (0.14) | 100 | ahead of 100 of 100 peers |
Inputs: EBIT -$23.3M; free cash flow -$18.9M; book equity $10.4M; sales $1.2M; debt $143,000; cash $10.1M.
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (88.8%) | ✗ fail[5,7] |
| Operating cash flow above zero | -$18.6M | ✗ fail[6] |
| Return on assets improved | 43.4 pts | ✓ pass[5,7,22,24] |
| Operating cash flow exceeds net income | $4.1M | ✓ pass[5-6] |
| Long-term leverage fell | n/a[1,7,22] | |
| Current ratio improved | (626.7 pts) | ✗ fail[16-17,25-26] |
| No new shares issued | n/a | |
| Gross margin improved | (11.8 pts) | ✗ fail[2,4,8-9] |
| Asset turnover improved | (15.1 pts) | ✗ fail[2,7,9,22] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $10.1M[3] |
| Operating cash flow, four quarters | -$20.4M[3,6,27-30] |
| Months of runway | 5.9 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 58 |
| 10-Q received Aug 12, 2026 | |
| Median daily dollar volume | $283,317 |
| 63 sessions | |
| Days since newest grade input | 206 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $10.3M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $1.2M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $10.1M | 2026-06-30 | 2026-08-12 | 10-Q | filing · viewer · series |
| 4 | gross profit | us-gaap:GrossProfit | $803,000 | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 5 | net income | us-gaap:NetIncomeLoss | -$22.7M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 6 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$18.6M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 7 | assets | us-gaap:Assets | $25.6M | 2024-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 8 | gross profit | us-gaap:GrossProfit | $1.9M | 2024-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 9 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $2.4M | 2024-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 10 | gross profit | us-gaap:GrossProfit | $221,000 | 2023-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 11 | revenue | us-gaap:Revenues | $709,000 | 2023-12-31 | 2024-02-27 | 10-K | filing · viewer · series |
| 12 | gross profit | us-gaap:GrossProfit | $497,000 | 2022-12-31 | 2024-02-27 | 10-K | filing · viewer · series |
| 13 | revenue | us-gaap:Revenues | $1.2M | 2022-12-31 | 2024-02-27 | 10-K | filing · viewer · series |
| 14 | gross profit | us-gaap:GrossProfit | $590,000 | 2021-12-31 | 2023-03-14 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:Revenues | $1.3M | 2021-12-31 | 2023-03-14 | 10-K | filing · viewer · series |
| 16 | current assets | us-gaap:AssetsCurrent | $5.5M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 17 | current liabilities | us-gaap:LiabilitiesCurrent | $4.1M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 18 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$132.3M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 19 | operating income | us-gaap:OperatingIncomeLoss | -$23.3M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 20 | book equity | us-gaap:StockholdersEquity | $5.7M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 21 | liabilities | us-gaap:Liabilities | $4.6M | 2025-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 22 | assets | us-gaap:Assets | $12.1M | 2023-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 23 | assets | us-gaap:Assets | $27.4M | 2022-12-31 | 2024-02-27 | 10-K | filing · viewer · series |
| 24 | net income | us-gaap:NetIncomeLoss | -$16.0M | 2024-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 25 | current assets | us-gaap:AssetsCurrent | $19.6M | 2024-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 26 | current liabilities | us-gaap:LiabilitiesCurrent | $2.6M | 2024-12-31 | 2026-03-17 | 10-K | filing · viewer · series |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$10.0M | 2026-06-30 | 2026-08-12 | 10-Q | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$4.4M | 2026-03-31 | 2026-05-13 | 10-Q | filing · viewer · series |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$13.3M | 2025-09-30 | 2025-11-04 | 10-Q | filing · viewer · series |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.3M | 2025-06-30 | 2026-08-12 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 96.8 is 16.8 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
